A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Durvalumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms HAWK
- Sponsors AstraZeneca
- 12 Sep 2017 Preliminary results (data cut off Sept 26, 2016) presented at the 42nd European Society for Medical Oncology Congress
- 12 Aug 2017 This trial has been completed in Germany (End date: 2017-08-02).
- 28 Apr 2017 Planned End Date changed from 1 Aug 2017 to 30 Mar 2018.